ONWARD MEDICAL BV EO -12 - Asset Resilience Ratio

Latest as of June 2024: 16.01%

ONWARD MEDICAL BV EO -12 (63E) has an Asset Resilience Ratio of 16.01% as of June 2024. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.

Liquid Assets

€7.50 Million

≈ $8.77 Million USD Cash + Short-term Investments

Total Assets

€46.85 Million

≈ $54.78 Million USD All company assets

Resilience Assessment

Good

Financial Resilience Level

Asset Resilience Ratio Trend (2022–2022)

This chart shows how ONWARD MEDICAL BV EO -12's Asset Resilience Ratio has changed over time. See how financially flexible is ONWARD MEDICAL BV EO -12 to measure the company's free cash flow as a share of total liabilities.

Liquid Assets Composition Over Time

This chart breaks down ONWARD MEDICAL BV EO -12's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see 63E company net worth.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	€0.00	0%
Short-term Investments	€7.50 Million	16.01%
Total Liquid Assets	€7.50 Million	16.01%

Asset Resilience Insights

Good Liquidity Position: ONWARD MEDICAL BV EO -12 maintains a healthy 16.01% of assets in liquid form.
This level provides good financial flexibility while maintaining productive asset deployment.
The company has significant short-term investments, indicating active treasury management.

ONWARD MEDICAL BV EO -12 Industry Peers by Asset Resilience Ratio

Compare ONWARD MEDICAL BV EO -12's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Samsung Biologics Co Ltd KO:207940	Biotechnology	5.66%
Revolution Medicines Inc NASDAQ:RVMD	Biotechnology	65.10%
Abivax SA PA:ABVX	Biotechnology	2.34%
Asymchem Laboratories Tian Jin Co Ltd SHE:002821	Biotechnology	5.07%
Ligand Pharmaceuticals Incorporated NASDAQ:LGND	Biotechnology	43.36%
SOLENO THERAPEUT. DL-001 F:6XC	Biotechnology	41.74%
REMEGEN CO. LTD YC 1 F:REG	Biotechnology	16.77%
Tibet Cheezheng Tibetan Medicine Co Ltd SHE:002287	Biotechnology	37.31%

Annual Asset Resilience Ratio for ONWARD MEDICAL BV EO -12 (2022–2022)

The table below shows the annual Asset Resilience Ratio data for ONWARD MEDICAL BV EO -12.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2022-12-31	26.11%	€20.00 Million ≈ $23.38 Million	€76.59 Million ≈ $89.55 Million	--

pp = percentage points

About ONWARD MEDICAL BV EO -12

F:63E Germany Biotechnology

Market Cap

$197.93 Million

€169.30 Million EUR

Market Cap Rank

#16668 Global

#1586 in Germany

Share Price

€2.44

Change (1 day)

+0.41%

52-Week Range

€2.42 - €5.56

All Time High

€12.92